Everence Capital Management Inc Supernus Pharmaceuticals, Inc. Transaction History
Everence Capital Management Inc
- $1.54 Billion
- Q4 2024
A detailed history of Everence Capital Management Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Everence Capital Management Inc holds 5,620 shares of SUPN stock, worth $172,871. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,620
Previous 7,570
25.76%
Holding current value
$172,871
Previous $236,000
13.98%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding SUPN
# of Institutions
302Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$320 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$189 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$149 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$88.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$80.9 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.65B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...